News - Dermatologicals

Filter

Current filters:

Dermatologicals

Popular Filters

1 to 25 of 131 results

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28-07-2014

The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors…

AfamelanotideAustraliaClinuvel PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinScenesse

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

LEO Pharma strikes global dermatology deal with KLOK Tech

LEO Pharma strikes global dermatology deal with KLOK Tech

16-07-2014

Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies,…

Acne vulgarisDermatologicalsGlobalKLOX TechnologiesLEO PharmaLicensingPharmaceutical

Ipsen and Galderma expand neurotoxins partnership

Ipsen and Galderma expand neurotoxins partnership

11-07-2014

French drugmaker Ipsen and global dermatology and skin health company Galderma have expanded the scope…

Botulinum toxinDermatologicalsGaldermaGalderma InternationalIpsen

Stada Arz acquires Flexitol rights for UK and Ireland

Stada Arz acquires Flexitol rights for UK and Ireland

10-07-2014

Thornton & Ross, the UK subsidiary of German generic and branded drugmaker Stada Arzneimittel, has purchased…

DermatologicalsFlexitolIrelandMergers & AcquisitionsPharmaceuticalSTADA ArzneimittelThornton & RossUK

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

10-07-2014

Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating…

DermatologicalsetanerceptNovartisPharmaceuticalPsoriasisResearchsecukinumabUSA

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

US FDA grants Valeant approval for Jublia NDA

US FDA grants Valeant approval for Jublia NDA

09-06-2014

Canadian drugmaker Valeant Pharmaceuticals International’s US subsidiary has received approval from…

CanadaDermatologicalsefinaconazoleJubliaPharmaceuticalRegulationUS Food and Drug AdministrationValeant Pharmaceuticals

Positive Ph III results with Cubist’s Sivextro in ABSSSI

Positive Ph III results with Cubist’s Sivextro in ABSSSI

06-06-2014

USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDermatologicalsPharmaceuticalResearchSivextro

High level of innovation seen in psoriasis treatment pipeline

High level of innovation seen in psoriasis treatment pipeline

29-05-2014

Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation…

BiotechnologyBiotest AGDermatologicalsInflammatory diseasesResearchtregalizumab

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

28-05-2014

US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

Akorn to acquire VersaPharm for $440 million

Akorn to acquire VersaPharm for $440 million

10-05-2014

Following swiftly on its completion of the acquisition of Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million…

AkornDermatologicalsGenericsMergers & AcquisitionsVersaPharm

New psoriasis therapies go head-to-head with existing drugs

06-05-2014

Three promising new drug classes are heating up the market for moderate-to-severe plaque psoriasis therapeutics,…

AlphaCytokinesDermatologicalsGlobalImmunologyMarkets & MarketingModerate-to-severe plaque psoriasisPharmaceuticalPharmacology

Pierre Fabre gains EU approval for Hemangiol, for proliferating infantile hemangioma

Pierre Fabre gains EU approval for Hemangiol, for proliferating infantile hemangioma

06-05-2014

French drugmaker Pierre Fabre Dermatologie Laboratories has obtained European Commission authorization…

DermatologicalsEuropeHemangeolHemangiolPharmaceuticalPierre FabreRegulation

Free drug samples can change prescribing habits of US dermatologists

17-04-2014

The availability of free medication samples in dermatology offices in the USA appears to change prescribing…

DermatologicalsMarkets & MarketingPharmaceuticalUSA

Aqua’s acquisition to push Almirall in US dermatology market

03-04-2014

Spain’s largest drugmaker, Almirall (ALM: MC), announced at the end of last year the acquisition of…

AlmirallAqua PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceutical

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

31-03-2014

Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

Real world data shows that Stelara offers lower rates of psoriasis infection

Real world data shows that Stelara offers lower rates of psoriasis infection

27-03-2014

New interval findings from an international prospective disease-based registry provide a review of important…

DermatologicalsJanssenPharmaceuticalResearchStelara InjectionUSA

1 to 25 of 131 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top